Composition

Abstract

To provide a novel technique that suppresses crystallization and precipitation of tranexamic acid species within a composition.SOLUTION: A composition contains the following components (A) to (C): (A) 0.1 mass% or more and 5 mass% or less of at least one selected from tranexamic acid and salts thereof; (B) 0.01 mass% or more and 2 mass% or less of diisopropylammonium dichloroacetate; and (C) water.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a composition. [Background technology]

[0002] A technology for suppressing crystal precipitation in a composition containing tranexamic acid is described in Patent Document 1 (JP 2018-48097 A). This document describes a cosmetic or topical skin preparation containing tranexamic acid or a derivative or a salt thereof and phytic acid or a salt thereof (claim 1), and states that such cosmetic or topical skin preparation sufficiently suppresses crystal precipitation of tranexamic acid, and can reduce concerns about crystal precipitation of tranexamic acid even when tranexamic acid is formulated at a high concentration (paragraph 0007). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Application Laid-Open No. 2018-48097 Summary of the Invention [Problem to be solved by the invention]

[0004] The present invention provides a new technique for inhibiting crystal precipitation of tranexamic acids in a composition. [Means for solving the problem]

[0005] According to the present invention, there are provided the following composition, crystal precipitation inhibitor, and crystal precipitation inhibitor method. [1] The following components (A) to (C): (A) at least one member selected from the group consisting of tranexamic acid and its salts, 0.1% by mass or more and 5% by mass or less (B) Diisopropylamine dichloroacetate 0.01% by mass or more and 2% by mass or less (C)Water A composition comprising: [2] The composition according to [1], wherein the content of the component (C) is 50% by mass or more based on the total mass of the composition. [3] The composition according to [1] or [2], wherein the mass ratio ((B) / (A)) of the content of component (B) to the content of component (A) in the composition is 0.04 or more and 1 or less. [4] The composition according to any one of [1] to [3], further comprising a component (D): a polyhydric alcohol. [5] The composition according to any one of [1] to [4], which is a cosmetic or a topical skin preparation. [6] Components (A) and (C) below: (A) at least one member selected from the group consisting of tranexamic acid and salts thereof (C)Water A crystal precipitation inhibitor of a composition comprising the above, which comprises the following component (B): (B) Diisopropylamine dichloroacetate [7] Components (A) and (C) below: (A) at least one member selected from the group consisting of tranexamic acid and salts thereof (C)Water A method for inhibiting crystal precipitation, comprising adding the following component (B) to a composition comprising the above: (B) Diisopropylamine dichloroacetate [Effects of the Invention]

[0006] According to the present invention, it is possible to inhibit the precipitation of crystals of tranexamic acids in a composition. DETAILED DESCRIPTION OF THE INVENTION

[0007] Hereinafter, an embodiment of the present invention will be described. In this embodiment, the composition may contain each component either alone or in combination of two or more. In this specification, the symbol "to" indicating a numerical range means "greater than or equal to" or "less than or equal to," and both of the numerical values at both ends are included.

[0008] (composition) In this embodiment, the composition contains the following components (A) to (C). (A) at least one member selected from the group consisting of tranexamic acid and its salts, 0.1% by mass or more and 5% by mass or less (B) Diisopropylamine dichloroacetate 0.01% by mass or more and 2% by mass or less (C)Water

[0009] The composition of this embodiment contains components (A) and (B) in combination with component (C), which effectively prevents precipitation of component (A) in the composition. This allows the composition to have excellent quality stability. Furthermore, this embodiment also makes it possible to prevent precipitation of component (A) when the composition is stored at room temperature, for example, around 25°C.

[0010] Here, the presence or absence of crystal precipitation can be evaluated by, for example, visually inspecting the composition. Alternatively, the composition may be dropped or applied to a substrate, and the presence or absence of particulate matter may be visually or tactilely inspected to determine the presence or absence of crystal precipitation. Examples of substrates include skin such as the hand; and flat plates such as resin and glass. The presence or absence of crystal precipitation can also be confirmed by checking the changes in the turbidity, absorbance, transmittance, etc. of the composition before and after storage. For example, the absorbance in the visible region (e.g., 660 nm) of the composition after storage at 25°C for 48 hours in a BioLite 24-well Multidish (manufactured by Thermo Fisher Scientific) can be measured using an EnSpire Multimode Plate Reader spectrophotometer (manufactured by PerkinElmer Japan). The absorbance (25°C) at a wavelength of 660 nm after storage at 25°C for 48 hours is, for example, 1 or less, preferably 0.8 or less, more preferably 0.6 or less, and even more preferably 0.4 or less. Specifically, the absorbance is 0 or more, and may be 0.01 or more. Furthermore, the change in absorbance (25°C) at 660 nm of the composition after storage for 48 hours at 25°C is preferably 0.3 or less, more preferably 0.2 or less, and even more preferably 0.1 or less. Specifically, the change in absorbance is 0 or more, and may be 0.01 or more. Each component will be described below.

[0011] (Component (A)) Component (A) is at least one selected from the group consisting of tranexamic acid and its salts. Component (A) can be produced by known methods, or commercially available products can be used. For example, tranexamic acid is listed in the 18th edition of the Japanese Pharmacopoeia.

[0012] Specific examples of salts of tranexamic acid salts include hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; Inorganic acid salts such as nitrates, perchlorates, sulfates, and phosphates; Alkanesulfonates having from 1 to 4 carbon atoms, such as methanesulfonates, trifluoromethanesulfonates, and ethanesulfonates; arylsulfonates such as benzenesulfonates and p-toluenesulfonates; organic acid salts such as acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate, maleate, etc.; alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; Organic amine salts such as N-methylmorpholine salts, triethylamine salts, tributylamine salts, diisopropylethylamine salts, dicyclohexylamine salts, N-methylpiperidine salts, pyridine salts, 4-pyrrolidinopyridine salts, and picoline salts; and Examples thereof include one or more salts selected from the group consisting of salts with amino acids such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamic acid salts, and aspartic acid salts.

[0013] Component (A) preferably contains tranexamic acid, more preferably tranexamic acid, which is expected to have anti-inflammatory and whitening effects.

[0014] The content of component (A) in the composition is 0.1% by mass or more, preferably 0.5% by mass or more, and more preferably 1% by mass or more, based on the total mass of the composition, which allows the desired effects such as anti-inflammatory activity and melanin production inhibitory activity to be more reliably obtained. Furthermore, the content of component (A) in the composition is 5% by mass or less, and preferably 3% by mass or less, based on the total mass of the composition, which can prevent a decrease in the solubility of component (A) in the composition.

[0015] (Component (B)) Component (B) is diisopropylamine dichloroacetate (DADA). Component (B) is a known substance and is listed, for example, in the Japanese Pharmacopoeia Non-Drug Standards 2002. Component (B) can be produced by a known method, or a commercially available product can be used.

[0016] The content of component (B) in the composition is 0.01% by mass or more, preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and even more preferably 0.15% by mass or more, based on the total mass of the composition, which makes it possible to more stably suppress crystal precipitation. The content of component (B) in the composition is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1% by mass or less, based on the total mass of the composition, which is expected to result in a formulation that is less irritating to the skin.

[0017] The mass ratio ((B) / (A)) of the content of component (B) to the content of component (A) in the composition is, for example, 0.03 or more, preferably 0.04 or more, more preferably 0.05 or more, and even more preferably 0.08 or more. This makes it possible to more stably suppress precipitation of component (A). Furthermore, the mass ratio ((B) / (A)) is, for example, 1.1 or less, preferably 1 or less, more preferably 0.7 or less, and even more preferably 0.4 or less. This may result in a formulation with better stability when other components are added. Furthermore, precipitation of component (A) can be efficiently suppressed with a smaller amount added.

[0018] (Component (C)) Component (C) is water. Specific examples of component (C) include those used in various preparations such as cosmetics, quasi-drugs, and pharmaceuticals, and more specifically, at least one selected from the group consisting of purified water, hot spring water, deep sea water, and steam-distilled water from plants can be used.

[0019] The content of component (C) in the composition can be, for example, the remainder after excluding components other than component (C) in the composition. The content of component (C) in the composition is preferably 50% by mass or more, more preferably 70% by mass or more, and even more preferably 80% by mass or more, based on the total mass of the composition. This allows each component to be dissolved more stably, and also allows the desired properties to be stably imparted. The content of component (C) in the composition is less than 100% by mass, specifically 99.89% by mass or less, preferably 99% by mass or less, and more preferably 98% by mass or less, which allows the composition to have the desired properties more stably.

[0020] The composition may further contain components other than components (A) to (C), and may, for example, contain the following component (D).

[0021] (Component (D)) Component (D) is a polyhydric alcohol. By further including component (D) in the composition, precipitation of component (A) can be more stably suppressed.

[0022] As component (D), for example, glycerins such as glycerin, diglycerin, and polyglycerin; sugar derivatives such as sugar alcohols (e.g., one or more selected from the group consisting of sorbitol, erythritol, and xylitol), methyl gluceth, and hydrogenated starch hydrolysates; Examples of the glycol include one or more selected from the group consisting of glycols such as isoprene glycol, 1,2-propylene glycol (PG), dipropylene glycol (DPG), polyethylene glycol (PEG), ethoxydiglycol, 1,3-butylene glycol (BG), and diethylene glycol monoethyl ether.

[0023] Component (D) is preferably a polyhydric alcohol having a molecular weight of 2000 or less, more preferably a polyhydric alcohol having a molecular weight of 1000 or less, more preferably a polyhydric alcohol having a molecular weight of 500 or less, even more preferably a polyhydric alcohol having a molecular weight of 200 or less, and even more preferably one or more compounds selected from the group consisting of BG, DPG, and glycerin. This makes it possible to more stably suppress the precipitation of component (A).

[0024] The content of component (D) in the composition is preferably 0.1% by mass or more, more preferably 1% by mass or more, and even more preferably 3% by mass or more, based on the total mass of the composition, which more effectively suppresses water evaporation and further suppresses precipitation due to drying. The content of component (D) in the composition is preferably 20% by mass or less, more preferably 15% by mass or less, and even more preferably 10% by mass or less, based on the total mass of the composition, thereby enabling the production of a formulation that is less irritating to the skin and highly safe.

[0025] In addition to the above-mentioned components, the composition may contain various components used in ordinary cosmetics, quasi-drugs, pharmaceuticals, etc., as appropriate, provided that the effects of the present invention are not impaired. For example, the composition may contain one or more components selected from the group consisting of oily components, UV absorbers, UV scattering agents, moisturizers, surfactants, pH adjusters, water-soluble polymers, thickeners, skin protectants, plant extracts, preservatives, chelating agents (sequestering agents), antioxidants, pearlizing agents, colorants, cooling agents, and fragrances (excluding components (A) to (D)).

[0026] Of these, the oily components specifically include one or more selected from the group consisting of fats and oils (vegetable oils, etc.) such as olive oil, shea butter, grape seed oil, etc.; waxes such as jojoba oil; hydrocarbon oils such as squalane, liquid paraffin, petrolatum, paraffin wax, etc.; ester oils such as octyldodecyl myristate, ethylhexyl palmitate, isopropyl myristate, tri(caprylic / capric acid)glyceryl, etc.; higher alcohols such as cetyl alcohol, stearyl alcohol, etc.; higher fatty acids, and silicone oils. The content of the oily component in the composition may be, for example, 0.01 to 40% by mass, or 1 to 10% by mass, relative to the total mass of the composition.

[0027] Specific examples of surfactants include one or more selected from the group consisting of nonionic surfactants; ionic surfactants such as anionic surfactants and cationic surfactants; and amphoteric surfactants.

[0028] Among these, examples of nonionic surfactants include polyoxyethylene (hereinafter, abbreviated as "POE") sorbitan monolaurate, POE sorbitan monopalmitate, POE sorbitan monostearate (e.g., Polysorbate-60), POE sorbitan tristearate, POE sorbitan monooleate (e.g., Polysorbate-80), and POE sorbitan tetraoleate fatty acid esters; POE sorbitol fatty acid esters such as POE sorbitol monolaurate, POE sorbitol monooleate, POE sorbitol pentaoleate, and POE sorbitol monostearate; POE glycerin fatty acid esters such as POE glyceryl monostearate, POE glyceryl monoisostearate, and POE glyceryl triisostearate; POE fatty acid esters such as POE monooleate, POE monostearate (PEG-75 stearate), POE distearate, and POE monodiolate; POE alkyl ethers such as POE lauryl ether, POE oleyl ether, POE stearyl ether, POE behenyl ether (e.g., Beheneth-10), POE octyldodecyl ether (e.g., Octyldodeceth-20), and POE cholestanol ether; POE Octylphenyl Ether, POE Nonylphenyl Ether, POE Dinonylphenyl Ether, POE Alkylphenyl Ether; POE polyoxypropylene (hereinafter, abbreviated as "POP") alkyl ethers such as polyoxyethylene polyoxypropylene decyltetradecyl ether (for example, PPG-6 decyltetradeceth-30, PPG-13 decyltetradeceth-24, PPG-20 decyltetradeceth-10); POE hydrogenated castor oil; Sorbitan fatty acid esters such as sorbitan monooleate, sorbitan monoisostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexylate, and diglycerol sorbitan tetra-2-ethylhexylate; Glycerin fatty acid esters such as glycerin monocottonseed oil fatty acid, glycerin monoerucate, glycerin sesquioleate, glycerin monostearate (e.g., lipophilic glyceryl monostearate), glyceryl oleate pyroglutamate, and glyceryl stearate malate; polyglycerin fatty acid esters such as polyglyceryl monolaurate, polyglyceryl monomyristate (e.g., polyglyceryl-10 myristate), polyglyceryl monooleate, polyglyceryl monostearate, polyglyceryl distearate, and polyglyceryl diisostearate (e.g., polyglyceryl-10 diisostearate); propylene glycol fatty acid esters such as propylene glycol monostearate; glycerin alkyl ethers such as 1-heptyl glyceryl ether, 1-(2-ethylhexyl) glyceryl ether, 1-octyl glyceryl ether, 1-decyl glyceryl ether, and 1-dodecyl glyceryl ether; Sucrose fatty acid esters, such as sucrose stearate; and Examples thereof include one or more selected from the group consisting of alkyl glucosides such as cetostearyl glucoside.

[0029] The number of carbon atoms in the fatty acid or alkyl group in the nonionic surfactant is preferably 6 or more, more preferably 10 or more, even more preferably 12 or more, still more preferably 14 or more, and even more preferably 16 or more, and is preferably 24 or less, more preferably 22 or less. This makes it possible to more stably suppress the occurrence of precipitation in the composition. In a similar respect, when the nonionic surfactant has at least one of a POE and a POP structure, the total number of moles of POE and POP added in the nonionic surfactant is preferably 1 or more, more preferably 3 or more, more preferably 5 or more, even more preferably 10 or more, still more preferably 15 or more, and is preferably 120 or less, more preferably 100 or less, even more preferably 60 or less, still more preferably 50 or less, and still more preferably 30 or less.

[0030] In a similar respect, the nonionic surfactant preferably comprises one or more surfactants selected from the group consisting of POE sorbitan fatty acid esters and glycerin fatty acid esters, more preferably a POE sorbitan fatty acid ester and glycerin stearate. The number of moles of POE added in the POE sorbitan fatty acid ester is preferably as described above.

[0031] The content of the nonionic surfactant in the composition is preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, based on the total mass of the composition, which makes it possible to more stably suppress the occurrence of precipitation in the composition. The content of the nonionic surfactant in the composition is preferably 20% by mass or less, more preferably 15% by mass or less, even more preferably 10% by mass or less, still more preferably 8% by mass or less, and even more preferably 5% by mass or less, based on the total mass of the composition, thereby further improving the stability of the composition.

[0032] Examples of the ionic surfactant include one or more selected from the group consisting of N-acylamino acid salts, N-acyltaurine salts, alkyl sulfates, alkyl sulfonates, alkyl betaines, and lecithin. The content of the ionic surfactant in the composition can be, for example, 0.05 to 10% by mass with respect to the total mass of the composition.

[0033] Examples of pH adjusters include one or more selected from the group consisting of sodium hydroxide, potassium hydroxide, arginine, lactic acid, aminomethylpropanol, 2-amino-2-methyl-1,3-propanediol, diethanolamine, triethanolamine, malic acid, citric acid and its salts, and phosphoric acid and its salts. The content of the pH adjuster in the composition can be, for example, 0.01 to 5% by mass with respect to the total mass of the composition.

[0034] Examples of thickeners include one or more selected from the group consisting of natural polymers such as guar gum, carrageenan, xanthan gum, sodium hyaluronate, pullulan, agar, and alginates; semi-synthetic polymers such as hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, and hydroxypropyl methyl cellulose stearoxy ether; and synthetic polymers such as carboxyvinyl polymers, polyacrylates, polyvinyl alcohol, and acrylic acid-alkyl methacrylate copolymers. The content of the thickener in the composition is preferably 0.001 to 5 mass %, more preferably 0.005 to 3 mass %, and even more preferably 0.01 to 2 mass %, based on the total mass of the composition.

[0035] A specific example of a skin protective agent is trehalose. The content of the skin protective agent in the composition can be, for example, 0.01 to 1% by mass based on the total mass of the composition.

[0036] Specific examples of preservatives include one or more selected from the group consisting of phenoxyethanol, benzoic acid and its salts, parahydroxybenzoic acid esters and its salts, salicylic acid and its salts, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, chlorhexidine gluconate, zinc pyrithione, piroctone olamine, methylisothiazolinone, and hinokitiol. The content of the preservative in the composition can be, for example, 0.01 to 1% by mass based on the total mass of the composition.

[0037] Examples of the chelating agent include one or more selected from the group consisting of disodium ethylenediaminetetraacetate, calcium disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate, tetrasodium ethylenediaminetetraacetate, sodium gluconate, sodium citrate, pentasodium diethylenetriaminepentaacetate, and sodium phytate. The content of the chelating agent in the composition can be, for example, 0.005 to 5% by mass with respect to the entire composition.

[0038] Next, the properties of the composition will be described. The composition is, for example, one selected from the group consisting of aqueous compositions; and emulsion compositions, such as oil-in-water emulsion compositions.

[0039] The composition is preferably fluid at 25°C, and more preferably liquid at 25°C. The Brookfield viscosity of the composition measured at 25°C with a Brookfield viscometer is, for example, about 0.05 to 20,000 mPa·s, preferably 0.05 to 1,000 mPa·s, more preferably 0.1 to 500 mPa·s, even more preferably 0.25 to 200 mPa·s, and still more preferably 0.25 to 100 mPa·s. Specifically, the Brookfield Brookfield viscosity of the composition can be measured using a Brookfield Brookfield viscometer (e.g., DV3T, spindle LV-2) with rotor number 1, a rotation speed of 60 rpm (for viscosity less than 150 mPa s) or 30 rpm (for viscosity of 150 mPa s or more), a measurement time of 1 minute, and an average value of n = 2.

[0040] The composition is applied in particular to the skin, preferably by spreading it on the skin. The composition is preferably a cosmetic such as a skin cosmetic, or an external preparation such as a skin external preparation, and may be a quasi-drug (medicated cosmetic) or a pharmaceutical, preferably a quasi-drug (medicated cosmetic). This allows for more reliable application to the desired area.

[0041] The dosage form of the external preparation can be, for example, a liquid preparation for external use including a liniment or a lotion; a cream; a spray preparation including an aerosol or a pump spray; or a gel. Here, the liniment is specifically a liquid or muddy external preparation that is rubbed into the skin. Furthermore, the lotion is specifically an external preparation in which the active ingredient is dissolved, emulsified, or finely dispersed in an aqueous liquid.

[0042] Examples of cosmetics include lotions, emulsions, serums, creams, gels, makeup removers, facial cleansers, sunscreens, makeup bases, foundations, lip balms, shampoos, conditioners, body soaps, etc. The cosmetics may be filled in pump spray containers or aerosol containers.

[0043] In this embodiment, the composition can be obtained, for example, by a production method including a step of mixing components (A) to (C) and, if necessary, other ingredients. The other ingredients can be selected, for example, depending on the dosage form of the composition. When the composition is an external preparation, it can be prepared according to the usual method described in, for example, the 18th edition of the Japanese Pharmacopoeia.

[0044] (Crystallization inhibitor, crystallization inhibition method) In this embodiment, the crystal precipitation inhibitor is a crystal precipitation inhibitor for a composition containing components (A) and (C), and contains component (B). The method for inhibiting crystal precipitation also includes blending component (B) with a composition containing components (A) and (C). These are suitable crystallization techniques that can be applied to a wide range of formulations containing components (A) and (C). Specific embodiments of the composition containing components (A) and (C) include the embodiment of the composition in the present embodiment described above.

[0045] Although the embodiments of the present invention have been described above, these are merely examples of the present invention, and various other configurations can also be adopted. [Example]

[0046] The present embodiment will be specifically described below with reference to examples, but the present embodiment is not limited to these examples.

[0047] (Examples 1 to 11, Comparative Example 1) In this example, an aqueous composition was prepared and evaluated.

[0048] (Method of preparing the composition) The components listed in Table 1 were mixed and dissolved at room temperature (25°C) to obtain the compositions of each example. The viscosity of the compositions obtained in each example was measured at 25°C using a Brookfield viscometer and was found to be 100 mPa·s or less.

[0049] (evaluation) The storage stability (suppression of crystal precipitation) of each composition was evaluated by the following procedure. That is, 1.0 g of the composition obtained in each example was weighed into a 20 mL beaker and allowed to stand in an open state under constant temperature and humidity conditions (25°C / 60% RH). The state of crystal precipitation after 48 hours was visually observed and evaluated according to the following criteria, with A and B being considered acceptable. The evaluation results are also shown in Table 1. A: No crystal precipitation B: There is a slight amount of crystallization, but it is within the acceptable range for use. C: Crystals precipitated, and usability was outside the acceptable range. D: Significant crystal precipitation

[0050] [Table 1]

[0051] (Example 12, Comparative Example 2) In this example, an oil-in-water emulsion composition was prepared and evaluated.

[0052] (Methods for preparing and evaluating the composition) First, the raw materials in Section A of Table 2 were heated to 80°C and mixed to obtain a mixture. Separately, the raw materials in Section B of Table 2 were heated to 80°C and stirred with a stirring rod to obtain a mixture. The mixture from Section B was added to the mixture from Section A, and the mixture was stirred and mixed at 1200 rpm for 3 minutes using an emulsifying and dispersing device (Labo-Lution, manufactured by Primix) and a stirring unit (Homodisper 2.5, manufactured by Primix) to obtain an emulsion. This was cooled to 45°C in a water bath while stirring with a stirrer. Next, in the examples, the raw materials from Section C in Table 2 were stirred with a stirrer at 25°C to obtain a mixture. This mixture was added to the cooled emulsion and stirred with a stirrer. Thereafter, the mixture was further stirred on a water bath and cooled to 35°C to obtain the composition of each example.

[0053] Details of the ingredients listed in Table 2 and Table 1 above are shown below. Liquid paraffin (mineral oil): MORESCO White P-55, manufactured by MORESCO Polyoxyethylene sorbitan monostearate (polysorbate 60): TS-10V, manufactured by Nippon Surfactant Kogyo Co., Ltd. Lipophilic glyceryl monostearate (glyceryl stearate): MGS-AV, manufactured by Nippon Surfactant Kogyo Co., Ltd. (A) Tranexamic acid: Tranexamic acid, manufactured by Kyowa Pharma Chemical Co., Ltd. (B) Diisopropylamine dichloroacetate: Liverall, manufactured by Qualitech Pharma

[0054] The compositions obtained in each example were evaluated according to the methods and criteria described above. The evaluation results are shown in Table 2.

[0055] [Table 2]

[0056] As can be seen from Tables 1 and 2, in each example, crystal precipitation in the composition after storage was suitably suppressed.

Claims

1. The following components (A) to (C): (A) at least one selected from the group consisting of tranexamic acid and salts thereof, 0.1% by mass or more and 5% by mass or less (B) Diisopropylamine dichloroacetate 0.01% by mass or more and 2% by mass or less (C) Water A composition comprising:

2. The composition according to claim 1, wherein the content of the component (C) is 50 mass% or more based on the total mass of the composition.

3. 3. The composition according to claim 1, wherein the mass ratio ((B) / (A)) of the content of the component (B) to the content of the component (A) in the composition is 0.04 or more and 1 or less.

4. The composition of claim 1 or 2, further comprising component (D): a polyhydric alcohol.

5. The composition according to claim 1 or 2, which is a cosmetic or an external skin preparation.

6. The following components (A) and (C): (A) at least one selected from the group consisting of tranexamic acid and salts thereof (C) Water The crystal precipitation inhibitor is a composition comprising the above, and further comprises the following component (B): (B) Diisopropylamine dichloroacetate

7. The following components (A) and (C): (A) at least one selected from the group consisting of tranexamic acid and salts thereof (C) Water A method for inhibiting crystal precipitation, comprising adding the following component (B) to a composition comprising: (B) Diisopropylamine dichloroacetate

Images